Sarcopenia attenuates the efficacy of PEGylated granulocyte colony-stimulating factor in preventing febrile neutropenia.

ABSTRACT:

Purpose

The aim of this study was to develop a predictive model integrating sarcopenia, PEGylated granulocyte colony-stimulating factor (PEG-G-CSF) administration, and conventional risk factors to predict febrile neutropenia (FN) and grade 4 neutropenia (G4 NP) in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP.

Methods

A retrospective cohort of 305 patients was analyzed. FN and G4 NP incidence rates after the first cycle were assessed along with predictors of these toxicities using multivariable logistic regression. Nomograms were developed and internally validated for risk prediction.

Results

PEG-G-CSF significantly reduced G4 NP incidence rates (37.3% vs. 53.3%) but had no significant effect on FN rates (20.9% vs. 17.1%). Sarcopenia was stro

SUBMITTER: Go SI 

PROVIDER: S-EPMC12137522 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature